Sp1 and Sp3 regulate basal transcription of the human APOBEC3G gene by Muckenfuss, Heide et al.
3784–3796 Nucleic Acids Research, 2007, Vol. 35, No. 11 Published online 21 May 2007
doi:10.1093/nar/gkm340
Sp1 and Sp3 regulate basal transcription
of the human APOBEC3G gene
Heide Muckenfuss, Julia K. Kaiser, Erika Krebil, Marion Battenberg,
Christina Schwer, Klaus Cichutek, Carsten Mu ¨nk* and Egbert Flory*
Division of Medical Biotechnology, Paul-Ehrlich-Institut, Paul-Ehrlich-Strasse 51-59, D-63225 Langen, Germany
Received March 28, 2007; Revised and Accepted April19, 2007
ABSTRACT
APOBEC3G (A3G), a member of the recently
discovered family of human cytidine deaminases,
is expressed in peripheral blood lymphocytes and
has been shown to be active against HIV-1 and other
retroviruses. To gain new insights into the transcrip-
tional regulation of this restriction factor, we cloned
and characterized the promoter region of A3G.
Transcriptional start sites were identified by
50-rapid amplification of cDNA ends analysis.
Luciferase reporter assays demonstrated that a
1025bp A3G promoter sequence (from  959 to
þ66 relative to the major transcriptional start site)
displayed constitutive promoter activity. In T cells,
the A3G promoter was not inducible by mitogenic
stimulation, interferon treatment or expression of
HIV-1 proteins. Using a series of 50 deletion promo-
ter constructs in luciferase reporter assays, we
identified a 180bp region that was sufficient for full
promoter activity. Transcriptional activity of this
A3G core promoter was dependent on a GC-box
(located at position  87/ 78 relative to the major
transcriptional start site) and was abolished after
mutation of this DNA element. Electrophoretic
mobility shift assays and chromatin immunopreci-
pitation assays demonstrated that the identified
GC-box represented a binding site for the ubiqui-
tous transcription factors specificity protein (Sp)
1 and Sp3.
INTRODUCTION
The recently discovered APOBEC3 family of cytidine
deaminases is considered to play an important role in
antiviral intrinsic immunity (1,2). In primates, the seven
paralogs APOBEC3A, B, C, DE, F, G, H (A3A-H) have
been described (3), and they appear to fulﬁll individual
functions. Human APOBEC3G (A3G), the most
prominent member of the APOBEC3 family has been
identiﬁed as the cellular restriction factor that is respon-
sible for inhibition of virion infectivity factor (Vif)-deleted
human immunodeﬁciency virus-1 (HIV-1) replication in
non-permissive cells (4). A3G is packaged into HIV-1vif
particles and causes C-to-U deaminations on the single-
stranded viral DNA during reverse transcription (5–8).
This leads to degradation of the uracile-containing DNA
by cellular repair mechanisms or to hypermutation of the
viral genome (5,6). As a result, only a marginal fraction of
the A3G-containing HIV-1 particles is able to complete
the replication cycle. In addition to the inhibition of HIV-
1, A3G restricts replication of other lentiviruses, gamma-
retroviruses, deltaretroviruses, spumaviruses, long-term-
inal-repeat (LTR)-retrotransposons, orthohepadnaviruses
and avihepadnaviruses (9–21). Interestingly, deamination
seems not to be the only A3G-mediated antiviral
mechanism; in the case of hepatitis B virus (HBV) and
human T cell leukemia virus type 1 (HTLV-1), A3G was
shown to restrict virus replication by deamination-
independent mechanisms (12,13,19,22–25). Another
member of the APOBEC3 family, APOBEC3F (A3F),
appears to have similar activities like A3G (26,27). A3F is
also packaged into HIV-1vif particles and induces
similar C-to-U deaminations, although the proteins
diﬀer in their target sequences speciﬁcity (26,28).
Furthermore, A3F proteins were detected in many tissues
that express A3G and are able to form heteromultimers
with A3G (26,29,30). Both proteins localize to mRNA
processing (P) bodies, cytoplasmic compartments involved
in the degradation and storage of non-translating mRNAs
(30,31).
A3G has been shown to be expressed in T cells, a
relevant cell target for HIV-1 in vivo, but little is known
about its regulation (4,29,32). There is a report describing
that mitogenic stimulation of T cells upregulates A3G
mRNA levels, but this was not analyzed on the transcrip-
tional level (33). Since the A3G promoter has not been
systematically analyzed so far, our aim was to clone the
A3G promoter and characterize its regulation in T cells.
In our study, we observed that A3G uses multiple
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50 deletions of the A3G promoter, we identiﬁed a 180bp
region that mediated basal transcription. In T cells,
transcriptional activity of this core promoter was not
inducible by mitogenic stimulation or interferon treat-
ment, but was dependent on a GC-box which was
recognized by Sp (speciﬁcity protein) 1 and Sp3 transcrip-
tion factors.
MATERIALS AND METHODS
Cell culture
The human T cell lines A3.01 and PM1 (NIBSC, UK)
and the human myeloid cell line U937 (NIBSC, UK)
were grown in complete RPMI 1640 medium supplemen-
ted with 10% fetal bovine serum, 2mM L-glutamine
and 100U/ml penicillin–streptomycin. The human
hepatic cell lines HepG2 and Huh7 (kindly provided by
Dr Thomas Pietschmann, Department of Molecular
Virology, University of Heidelberg) as well as HeLa cells
were maintained in Dulbecco’s high glucose modiﬁed
Eagle’s medium (DMEM) supplemented with 10%
fetal bovine serum, 2mM L-glutamine and 100U/ml
penicillin–streptomycin. Cells lines were incubated at
378C with 100% humidity in 5–7% CO2 and passaged
using standard cell culture techniques.
Plasmids
For cloning of an APOBEC3G promoter-driven reporter
plasmid, genomic DNA was prepared from the T cell line
PM1 using the DNeasy Kit (Qiagen). The DNA sequence
ranging from positions  959 to þ66 relative to the
identiﬁed transcription start was ampliﬁed via PCR
using the primers 3Gprom1025 (50-TGTGAACGCGT
TGCTGCAGGCCATCTGGATGTATATG-30) and
3Gpromreverse (50-ACAGCAGATCTAGGGACCTCT
GATAAAGACAGG-30). PCR reactions were performed
with Pwo DNA Polymerase (Roche) using the following
cycle conditions: one cycle 948C for 2min; 30 cycles 948C
for 30s, 588C for 60s, 728C for 60s; one cycle 728C for
7min. The amplicon was ligated into the promoterless
luciferase reporter plasmid pGL3-Basic (Promega) via
MluI and BglII restriction sites, which were introduced by
the primers. The resulting construct contained 1025bp
of the A3G promoter and was designated pGL3-
APOprom1025. Reporter plasmids containing shorter
fragments of the APOBEC3G promoter were constructed
using pGL3-APOprom1025 as template and the
following forward primers: for plasmid pGL3-
APOprom502 (containing sequence  436/þ66):
3Gprom502 (50-TGTGAACGCGTTCCATAACATGG
GGACAAGA-30); for plasmid pGL3-APOprom225
(containing sequence  159/þ66): 3Gprom225 (50-TGTG
AACGCGTCGAGGGCAGGATCCGGGAGT-30); for
plasmid pGL3-APOprom180 (containing sequence  114/
þ66): 3Gprom180 (50-TGTGAACGCGTTCTTGATGG
TGGAGAGGAGG-30); for plasmid pGL3-APOprom150
(containing sequence  84/þ66): 3Gprom150 (50-TGTGA
ACGCGTGCGGGACCACCAGGGGAGGGGCTT-30);
for plasmid pGL3-APOprom120 (containing sequence
 54/þ66): 3Gprom120 (50-TGTGAACGCGTTGC
TGGCTCAGCCTGGTGTG-30); for plasmid pGL3-
APOprom60 (containing sequence þ7/þ66): 3Gprom60
(50-TGTGAACGCGTCCCTTTGCAATTGCCTTG-30);
each in combination with the reverse primer
3Gpromreverse (described above). PCR reactions were
performed with Pfu Ultra Hotstart (Stratagene) using the
following cycle conditions: one cycle 948C for 2min; 30
cycles 948C for 45s, 588C for 45s, 728C for 60s; one cycle
728C for 7min. As for pGL3-APOprom1025, MluI and
BglII restriction sites were introduced via the primers and
PCR products were ligated into pGL3-Basic (Promega)
via these restriction sites. pGL3-APOprom180mut carries
two point mutations (bold) and was generated using
the primer 3GProm180mut (50-TGTGAACGCGTTCT
TGATGGTGGAGAGGAGGCTCCAGCTGTTCGGG
ACCACCAG-30) in combination with primer
3Gpromreverse. This PCR was performed with an
annealing temperature of 658C. pGL3promE1 (containing
nucleotides  114/ 85) and pGL3promE2 (containing
nucleotides  92/ 63) were constructed by annealing the
following single-stranded oligonucleotides: 114_85Plus
(50- CGCGTTCTTGATGGTGGAGAGGAGGCTCCA
GCTGGA-30) and 114_85Minus (50- GATCTCCA
GCTGGAGCCTCCTCTCCACCATCAAGAA-30)o r
92-63Plus (50-CGCGTCCAGCTGGGCGGGACCACC
AGGGGAGGGGCA-30) and 92_63Minus (50-GATCT
GCCCCTCCCCTGGTGGTCCCGCCCAGCTGGA-30).
After annealing, the double-stranded oligonucleotides
which contained the respective 30bp of the APOBEC3G
promoter and sticky ends compatible with MluI and BglII
restriction sites were ligated into the pGL3-Promoter
(Promega) vector. The sequences of all constructed
plasmids were veriﬁed by sequence analysis. Nucleotide
 219 of the cloned APOBEC3G promoter diﬀers from the
sequence in the database (GenBank
TM accession number
DQ147772). An A-to-C substitution is present at this
position. Numbering is relative to the major transcrip-
tional start site we identiﬁed.
The reporter plasmids pGL3-Control and phRG-TK
were purchased from Promega. pGL2-CVX contains two
repeats of the IFN-responsive GAS (gamma activated
sequence) elements (GATCTGGATTTAGAGTAATA
TGAAACTGAAAGTACTTCG) of the guanylate-bind-
ing protein (GBP) gene in front of a CMV minimal
promoter and was kindly provided by Ute Pa ¨ gelow and
Mario Ko ¨ ster from the Helmholtz-Zentrum fu ¨ r
Infektionsforschung. Plasmid pNL4-3 (NIBSC, UK)
contains the full-length HIV-1NL4-3 genome and has
been described previously (34). pcDNA3.1Vif was gener-
ously provided by Nathaniel R. Landau from the Salk
Institute, La Jolla. It was generated by amplifying the Vif
gene from pNL4-3 and ligating it into the pcDNA3.1
vector via BamHI and XhoI restriction sites. A 30-WPRE
element was included into the XhoI site. pBS-kRSPA-
TatHIV-1(NL4-3) was constructed by amplifying the two
exons of Tat via PCR reaction using the molecular clone
pNL4-3 as template and the following primer sets:
exon1, 5U ¨ Xho1HIV-Tat1Plus (50-GCATGCTCGAGAT
GGAGCCAGTAGATCCTAG-30) and HIV-Tat1Minus
(50-TGCTTTGATAGAGAAGCTTGATG-30); exon2,
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CTCCCAATCCCG-30) and 5U ¨ Spe1HIV-Tat2Minus
(50-GACGTACTAGTCTATTCCTTCGGGCCTGTC-30).
XhoI and SpeI restriction sites were introduced via the
primers. The sense-primer of exon2 starts with a 15-mer
which is homologous to the 30 end of exon1 and necessary
for fusion of both exons. PCRs were performed with
Expand High Fidelity PCR System (Roche) using the
following conditions: one cycle 948C for 3min; 35 cycles
948C for 45s, 558C for 45s, 688C for 45s; one cycle 688C
for 7min. For fusion of both exons, the following
PCR conditions were applied: one cycle 948C for 3min;
35 cycles 948C for 45s, 588C for 45s, 688C for 60s. After
10 cycles without primers, the sense-primer of exon1 and
the antisense-primer of exon2 were added for the
remaining cycles. The resulting amplicon was ligated
into the pBS-kRSPA vector (35) via XhoI and SpeI
restriction sites.
50-Rapid amplification ofcDNA endsanalysis (RACE)
Total RNA was isolated from A3.01T cells using RNeasy
mini kit (Qiagen). The transcriptional start sites of A3G
were identiﬁed using the 50/30 RACE Kit, 2nd Generation
(Roche) according to the manufacturer’s instructions.
The following primers were used: RACE-APO3G1
(50-TATCCCTTGTACACTTTGT-30) for cDNA synthe-
sis, RACE-APO3G2 (50-CATACTCCTGGTCACGAT-
30) for the ﬁrst PCR and RACE-APO3Gnest
(50-GAATACACCTGGCCTCGAA-30) for the nested
PCR. Reaction products were analyzed by agarose gel
electrophoresis, puriﬁed using QIAquick gel extraction kit
(Qiagen), T/A-cloned into vector pCR4-TOPO
(Invitrogen) and sequenced.
Luciferase assay
For transient transfection of A3.01 and U937 cells,
DMRIE-C transfection reagent (Life Technologies) was
used (36). Cells were seeded in 6-well tissue culture plates
(5 10
5cells per well) in 1.5ml Opti-MEM (Life
Technologies) containing 0.5mg ﬁreﬂy luciferase reporter
plasmid and 3.5ml DMRIE-C. After 4–5h of incubation,
1.5ml complete RPMI medium were added. HepG2 and
Huh7 cell lines were transfected using LipofectAMINE
Plus as recommended by the manufacturer (Life
Technologies). Brieﬂy, exponential growing cells
(1.5 10
6) were transfected with 5ml LipofectAMINE,
6ml PLUS reagent and the required amount of plasmid
DNA in a ﬁnal volume of 1ml Opti-MEM. Following 4h
of incubation, cells were washed in PBS and 3ml of
complete DMEM medium were added.
For cotransfection of reporter plasmids and siRNA
into HeLa cells, HiPerfect transfection reagent (Qiagen)
was used according to the manufacturer’s protocol
for cotransfection of adherent cells with siRNA and
plasmid DNA.
Two days after transfection of the respective cell lines,
cells were harvested in 100ml (suspension cells) or 300ml
(adherent cells) of Passive Lysis Buﬀer (Promega) and
luciferase assay was performed using the Dual Luciferase
Assay System (Promega) according to the manufacturer’s
instructions. As an internal control, 50ng (adherent cells)
or 100ng (suspension cells) of ph-RG-TK plasmid
(Promega), which constitutively expresses renilla luciferase
was cotransfected in every sample and ﬁreﬂy luciferase
activities were normalized to renilla luciferase activities.
Mean values ( SD) of a representative experiment
performed in triplicate are shown in the ﬁgures. For
stimulation of cells, ﬁnal concentrations of 20ng/ml TPA
(Sigma) or 30ng/ml IFN-a or 30ng/ml IFN-g (Tebu-Bio)
were applied approximately 15h before harvesting for
luciferase assay.
Electrophoretic mobility shiftassay(EMSA)
For preparation of nuclear extracts, 5 10
6 A3.01T cells
were washed in cold PBS and resuspended in 500ml buﬀer
A (10mM HEPES pH7.9, 10mM KCl, 0.1mM EDTA,
0.1mM EGTA, 1mM DTT, 0.5mM PMSF). After
incubation for 15min on ice, swollen cells were pressed
10 times through a syringe with a 26G needle and
centrifuged at 5000 r.p.m. for 5min. Pellets contained
the nuclei and were washed in buﬀer A for two times and
resuspended in 50ml buﬀer C (20mM HEPES pH 7.9,
400mM NaCl, 1mM EDTA, 1mM EGTA 1mM DTT,
1mM PMSF). After shaking for 30min at 48C and
centrifugation for 10min at 13 000 r.p.m., supernatants
were used as nuclear extracts.
EMSA probes were generated by annealing the follow-
ing complementary oligonucleotides: APO-Sp1/3, 50- CCA
GCTGGGCGGGACCACCAGGGGAGGGGC-30 and
50-GCCCCTCCCCTGGTGGTCCCGCCCAGCTGG-30;
APO-Sp1/3mut, 50- CCAGCTGTTCGGGACCACCAG
GGGAGGGGC-30 and 50- GCCCCTCCCCTGGTGG
TCCCGAACAGCTGG-30 according to standard proce-
dures. Nucleotides diﬀering from the original promoter
sequence are shown in bold type. A commercially
available Sp1 probe (sc-2502, referred to as Sp1cons)
was purchased from Santa Cruz Biotechnology. The
double-stranded oligonucleotides were 50 end-labeled
using T4 polynucleotide kinase (New England Biolabs)
and [g-
32P]ATP (3000Ci/mmol, Amersham) and puriﬁed
by using Nick G50 columns (Amersham).
For EMSA, 5mg of nuclear proteins were preincubated
on ice with 2mg of poly(dI-dC) (Roche) as an unspeciﬁc
competitor and 1mg of bovine serum albumin in
band shift buﬀer (50mM Tris, 150mM KCl, 5mM
EDTA, 2.5mM dithiothreitol, 20% Ficoll) for 15min.
32P-labeled oligonucleotides (50 000c.p.m.) were added in
a total volume of 20ml, incubated on ice for 20min
and loaded onto 5% native polyacrylamide gels in
0.5 Tris-borate-EDTA buﬀer. Upon fractionation, gels
were dried and exposed for autoradiography. For
competition experiments, 1- or 30-fold molar excess of
the unlabeled APO-Sp1/3 or APO-Sp1/3mut oligonucleo-
tides was added to the preincubation mixture. For
supershift experiments, 2mg Sp1 antibody (sc-59x, Santa
Cruz Biotechnology) or Sp3 antibody (sc-644x,
Santa Cruz Biotechnology) were added to the preincuba-
tion mixture and preincubation time was extended
to 30min.
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A3.01 cells were treated with RPMI culture medium
containing 1% formaldehyde for 10min. at 378C. Cells
were washed twice with ice-cold PBS and incubated for
10min. on ice after resuspension in SDS lysis buﬀer (ChIP
Assay Kit, Upstate). After centrifugation, pellets were
resuspended in MNase reaction buﬀer (10mM Tris-HCl
pH 7.5, 10mM NaCl, 3mM MgCl2, 1mM CaCl2,4 %
NP-40). DNA digestion was performed using 50 U
Micrococcal Nuclease (Fermentas) and 1 10
7 cells per
tube in a volume of 1.5ml. After 2min, reaction was
stopped by adding 30ml 200mM EGTA. Further steps
were performed using the Chromatin Immunoprecipita-
tion Assay Kit (Upstate) according to the manufacturer’s
instructions. 1 10
7 cells and 2mg antibody (Sp1(Pep2)
sc-59, Sp3(D-20) sc-644 or actin(H-196) sc-7210, Santa
Cruz Biotechnology) were used for each immunoprecipi-
tation. All buﬀers were freshly supplied with protease
inhibitors. After phenol/chloroform extraction and
ethanol precipitation, DNA was resolved in 16mlH 2O.
Immunoprecipitated DNA was detected by nested
PCR using 4ml of the resolved DNA in the ﬁrst PCR,
and 1ml for the nested PCR. For ampliﬁcation of
the A3G promoter, the following primers were used:
ChIP3Gplus 50-ccacggtggcctccgagggtga-30 and ChIP3G-
minus: 50-ctctccaccatcaagacagac-30 (1. PCR); ChIP3G2-
plus: 50-tactctccctccctgtcccca-30 and ChIP3G nested
minus: 50-aggctgatgcctccgcag-30 (nested PCR). Taq poly-
merase (Qiagen) was used together with the following
cycle conditions: one cycle 948C for 2min; 30 cycles 948C
for 30s, 608C for 60s, 728C for 2min; one cycle 728C
for 10min. As a negative control, a region in the A3G
gene was targeted using the primers ChIP3Gneg_plus:
50-taagtaccacccagagatgag-30 and ChIP3Gneg_minus:
50-catgatcttcatggtggcacg-30 for both PCR steps. PCR
conditions were the same as for the A3G promoter
sequence, with the exception that annealing temperature
was decreased to 558C.
RNA interference and westernblot analysis
Sp1 and Sp3 translation was silenced in HeLa cells
using the siRNA duplexes Hs_SP1_1_HP and
Hs_SP3_1_HP (Qiagen). A nonspeciﬁc siRNA (Qiagen)
was used as control. HeLa cells were transfected with 150
or 300ng siRNA per 6-well, using the HiPerfect transfec-
tion reagent (Qiagen) according to the manufacturer’s
protocol for reverse transfection of adherent cells in 6-well
plates.
Forty-eight hours after transfection, HeLa cells were
harvested for detection of Sp1 and Sp3 proteins.
Cells were washed in PBS, lysed in RIPA (25mM
Tris pH 8.0, 137mM NaCl, 1% Glycerol, 0.5% sodium
deoxycholate, 1% NP-40, 2mM EDTA pH 8, 0.1%
SDS and protease inhibitors) and lysates were cleared
by centrifugation. After boiling with Laemmli0s buﬀer,
samples were subjected to SDS–polyacrylamide gel
electrophoresis followed by transfer to a nitrocellulose
membrane. Sp1 and Sp3 proteins were detected
using a-Sp1(Pep2) antibody (sc-59, Santa Cruz) or a-
Sp3(D-20) antibody (sc-644, Santa Cruz) followed by
incubation with a-rabbit-HRP (Amersham Biosciences).
For detection of tubulin, a-tubulin (B5-1-2, Sigma) and
a-mouse-HRP (Amersham Biosciences) antibodies were
used. Signals were visualized by enhanced chemilumines-
cence (ECL, Amersham Biosciences).
RESULTS
Characterization ofthe transcriptional start sitesof
APOBEC3G by 50-RACE
To identify the transcriptional start sites (TSS) of
APOBEC3G (A3G) in A3.01T cells, we performed
50-rapid ampliﬁcation of cDNA ends analysis (RACE)
with A3G-speciﬁc primers (see Figure 1). Agarose gel
electrophoresis resolved the nested PCR products into
three bands of diﬀerent electrophoretic mobility with a
dominant middle band (Figure 2). For each band, the
DNA was cloned and sequence analysis of six or seven
individual transformants was performed. We observed
that the transcriptional start sites of the A3G gene were
located between 58 and 361nt upstream of the ATG
start codon (Figure 1). Although TSS were variable
and most sites were only detected once among the
19 clones analyzed, one TSS was identiﬁed in six
individual clones. This TSS was located 66nt upstream
of the start of the published A3G mRNA sequence
(GenBank
TM accession number NM021822) and we
deﬁned this position as the major transcriptional start
site of the A3G gene.
The corepromoter of A3G islocated within theregion
 114/þ66 relative tothe TSS
For characterization of the A3G promoter, we cloned
the 1025bp located at position  959/þ66 relative to the
identiﬁed transcription start into the promoterless
pGL3-Basic luciferase reporter plasmid and designated
the plasmid pGL3-Basic-APOprom1025. Similarly,
pGL3-APOprom502 (containing sequence  436/þ66),
pGL3-APOprom225 (containing sequence  159/þ66)
and further 50 deletion reporter constructs containing
180, 150, 120 or 60bp upstream of position þ65 were
generated (Figure 3A). In order to analyze transcriptional
activity, the luciferase reporter plasmids were transiently
transfected into A3.01T cells. Luciferase assays revealed a
 20-fold increased transcriptional activity of the 1025bp
sequence as compared to the empty vector, indicating that
we had identiﬁed an active A3G promoter sequence
(Figure 3B). This transcription rate was not signiﬁcantly
altered by the 50 deletions leading to the 502, 225 and
180bp fragments (Figure 3B). In contrast, a drop in
luciferase activity was observed in the case of the 150bp
fragment. This construct only retained 28% of the
transcriptional activity of the 180bp promoter in
A3.01T cells and activity of the 120bp fragment was
further reduced. Comparable reductions relative to the
activity of 180bp fragment were observed in the myeloid
cell line U937 and the hepatic cell lines HepG2 and
Huh7 (Figure 3C), indicating that the core promoter of
A3G is located within the region  114/þ66 relative to
the TSS.
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According to the current knowledge, APOBEC3G plays a
role in the innate defence against pathogens like HIV-1.
The latter has evolved a mechanism to counteract
A3G activity by expressing the regulatory protein Vif
(4). Vif induces proteasomal degradation of A3G and
additionally inhibits A3G activity by further mechanisms
(8,37–43). To investigate whether the overexpression of
HIV-1 proteins also inﬂuences A3G promoter activity,
we either expressed HIV-1 Vif or the HIV-1 Tat protein,
the latter has been shown to activate diﬀerent viral and
cellular promoters (44,45). In addition, increasing
amounts of the plasmid pNL4-3, containing the full-
length genome of HIV-1, were transfected. These con-
structs or the empty vector pcDNA3.1 were cotransfected
with the 1025bp construct into A3.01T cells. Luciferase
assays showed that the transcriptional activity of the A3G
promoter was not signiﬁcantly altered in the presence
of Vif, Tat or HIV-1NL4-3 (Figure 4A), suggesting that
HIV-1 is not modulating A3G expression on the
transcriptional level.
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CTCTTTCCCTTTGCAATTGCCTTGGGTCCTGCCGCACAGAGCGGCCTGTCTTTATCAGAGGTCCCTCTGCCAGGGGGAGGGCCCCAGAGAAAACCAGAAA
GAGGGTGAGAGACTGAGGAAGATAAAGCGTCCCAGGGCCTCCTACACCAGCGCCTGAGCAGGAAGCGGGAGGGGCCATGACTACGAGGCCCTGGGAGGTC
ACTTTAGGGAGGGCTGTCCTAAAACCAGAAGCTTGGAGCAGAAAGTGAAACCCTGGTGCTCCAGACAAAGATCTTAGTCGGGACTAGCCGGCCAAGGATG
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Figure 1. Sequence of the A3G promoter and the downstream region. The ﬁrst 1000bp upstream of the major TSS are shown in lower case, the ﬁrst
800bp of the transcribed sequence are shown in upper case. Introns are removed, but their positions are indicated. Arrows refer to transcriptional
start sites and their observed frequency is given by the numbers above. The primer binding sites for 50-RACE analysis and cloning of the luciferase
reporter constructs are underlined and the names of the primers are annotated. Gray and black arrowheads deﬁne the regions designated E1 and E2
which were cloned into vector pGL3-Promoter and used as EMSA probes. The ATG start codon and the identiﬁed Sp1/Sp3 transcription factor
binding site are shown in bold.
3
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Figure 2. 50-RACE analysis of the A3G cDNA. Agarose gel electro-
phoresis of size marker and A3G 50-RACE products after nested PCR
with primer RACE-APO3Gnest (see Figure 1 for primer details).
Arrowheads indicate the three resulting DNA bands which were cloned
and sequenced.
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cells is increased in response to mitogenic stimulation with
phorbol ester (46–48). In addition, interferons have been
described to upregulate A3G expression in hepatocytes
and macrophages (46,48). To investigate whether these
stimuli interfere with A3G promoter activity in T cells, we
transfected A3.01T cells with the 1025bp promoter or the
empty vector pGL3-Basic (vector) and treated the cells
with phorbol ester (TPA). The luciferase assay showed
that the  15-fold increased transcriptional activity of the
1025bp promoter relative to the empty vector was not
further enhanced by TPA treatment (Figure 4B), although
the functional activity of TPA was conﬁrmed by induction
of the SV40 promoter-containing reporter plasmid pGL3-
Control (data not shown). Similarly, treatment of A3.01T
cells transfected with the A3G promoter deletion con-
structs with IFN-a or IFN-g showed no eﬀect (Figure 4C).
Interestingly, a control plasmid (pGL2-CVX) containing
two IFN-responsive GAS (gamma activated sequence)
elements upstream of the luciferase reporter gene was only
induced by IFN-a in these cells (Figure 4C). Since two
reports describe A3G upregulation by interferons in
hepatocytes (47,48), we additionally performed the experi-
ment in the hepatic cell line HepG2. In line with these
publications, we observed an induction of the A3G
promoter by approximately 2-fold after IFN-a or IFN-g
stimulation (Figure 4D) with IFN-g being slightly more
potent. For both interferon types, induction of A3G
promoter activity was observed for all deletion constructs
except for the 60bp fragment, indicating that the
responsible region is located within the 60nt present in
the 120bp, but not in the 60bp fragment.
AGC-boxlocatedatposition 87/ 78oftheA3Gpromoteris
importantfortranscriptional activity
The reporter studies shown in Figure 3 had demonstrated
a drop in luciferase activity after deletion of the 30nt at
the 50 end of the 180bp core promoter. We therefore
inspected the 30bp sequence deleted in the 150bp
fragment and identiﬁed a GC-box at position  87/ 78
(see Figure 1). The sequence TGGGCGGGAC, which is
interrupted in the 150bp fragment, represents a variant of
the (G/T)GGGCGG(G/A)(G/A)(C/T) consensus motif
recognized by Sp1 and Sp3 transcription factors. To
analyze whether this putative Sp1/Sp3-binding site medi-
ates transcriptional activity of the 180bp core promoter,
we introduced two point mutations which changed the
sequence from TGGGCGGGAC to TGTTCGGGAC
(mutations shown in bold). This resulted in a 71%
reduction of the transcriptional activity compared to the
unmodiﬁed 180bp promoter (Figure 5A) and this value
was only marginally higher than the luciferase activity of
the 150bp fragment, indicating that the identiﬁed motif is
essential for basal activity of the A3G core promoter. To
further examine the transcriptional potency of the 30nt
present in the 180bp promoter, we cloned the region
 114/ 85 (containing all nucleotides which are
deleted in the 150bp fragment, designated E1) or
the region  92/ 63 (containing the putative Sp1/Sp3
motif, designated E2) into the vector pGL3-Promoter
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Figure 3. Luciferase activities of A3G promoter constructs in diﬀerent
cell lines. (A) A3G promoter 50 deletion constructs of diﬀerent sizes
were cloned into pGL3-Basic luciferase reporter plasmids. Numbering
is relative to the major TSS. A putative Sp1/Sp3 consensus site (gray
square) is depicted. (B) A3.01T cells were transiently transfected with
the A3G promoter deletion constructs. Numbers on the x-axis refer to
the length of the A3G promoter fragments in bp. (C) A3G promoter
plasmids were transfected into U937, HepG2 and Huh7 cell lines.
Numbers in the legends refer to the length of the A3G promoter
fragments in bp. After 48h, cells were harvested for luciferase assay.
Fireﬂy luciferase activities were normalized to coexpressed renilla
luciferase activities. Mean values ( SD) of a representative experiment
performed in triplicate are shown.
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3790 Nucleic Acids Research, 2007, Vol. 35, No. 11(see Figure 1). This vector contains a luciferase reporter
gene under the control of an SV40 promoter without
enhancer sequences, and putative transcriptionally active
sequences can be cloned upstream of the SV40 promoter.
Luciferase assays showed that the E1 element increased
SV40 promoter activity only by  2-fold (Figure 5B). In
contrast, the 30nt of E2 enhanced the transcriptional
activity of the SV40 promoter by  4.3-fold, indicating
that the intact GC-box present in the E2 element was
responsible for the strongly enhanced transcriptional
activity of the SV40 promoter.
Sp1and Sp3transcription factorsbindto the GC-box at
position  87/ 78of theA3G promoter
To investigate whether the GC-box represents a binding
site for the transcription factors Sp1 and Sp3, we
performed EMSA analyses with nuclear extracts isolated
from A3.01T cells. As probes, we radioactively labeled the
unmodiﬁed E2 sequence (nucleotides  92/ 63 of the A3G
promoter, probe designated APO-Sp1/3) or the same
region carrying the two point mutations described above
(probe designated APO-Sp1/3mut). As control, we used a
commercially available Sp1 consensus oligonucleotide
(Sp1cons), which is known to be recognized by Sp1
transcription factors. Four DNA–protein complexes
were observed in the presence of the APO-Sp1/3 probe
(Figure 6A). The upper two complexes were speciﬁc since
they disappeared in the presence of a 30-fold molar excess
of unlabeled APO-Sp1/3 probe (Figure 6A, lane 7).
Further conﬁrmation of the speciﬁcity of these DNA–
protein complexes was demonstrated by the inability of
the unlabeled APO-Sp1/3mut probe to abolish binding
(Figure 6A, lanes 12 and 13). As expected, the two speciﬁc
complexes were also present in the case of the Sp1cons
control probe (Figure 6A, lanes 2 and 3). In contrast,
none of these speciﬁc complexes was observed when the
mutated probe was used (Figure 6A, lanes 10 and 11),
conﬁrming that protein binding was dependent on the
identiﬁed GC-box. In order to characterize the complexes,
we performed supershift experiments using Sp1- and
Sp3-speciﬁc antibodies. The upper of the complexes
that appeared in combination with the Sp1cons or
APO-Sp1/3 probes, shifted in the presence of the Sp1
antibody (Figure 6B, lanes 3 and 7), whereas the lower
complex shifted in the presence of the Sp3 antibody
(Figure 6B, lanes 4 and 8). Taken together, the EMSA
Figure 4. A3G promoter activities after coexpression of HIV-1 proteins
or treatment with TPA or interferons. (A) A3.01T cells were
cotransfected with pGL3-Basic reporter plasmid containing the
1025bp A3G promoter and 1mg of Vif expression plasmid, 1mg Tat
expression plasmid or increasing amounts of HIV-1NL4-3 (0.1, 0.5 and
1mg). After 48h, cells were harvested for luciferase assay. Fireﬂy
luciferase activities were normalized to coexpressed renilla luciferase
activities. (B) A3.01T cells were transiently transfected with
pGL3-Basic reporter plasmid containing the 1025bp A3G promoter
or with empty vector. Fifteen hour before harvesting for luciferase
assay, a subset of the cell culture was stimulated with 20ng/ml TPA.
Forty-eight hour after transfection, luciferase assay was performed.
Fireﬂy luciferase activities were normalized to coexpressed renilla
luciferase activities and the values for the empty vectors (untreated
and TPA-stimulated) were set as 1. (C) A3.01T cells were transiently
transfected with the A3G promoter constructs or with the interferon-
responsive reporter plasmid pGL2-CVX (GAS). Fifteen hour before
harvesting for luciferase assay, a subset of the cell culture was
stimulated with 30ng/ml IFN-a or IFN-g. Forty-eight hour after
transfection, luciferase assay was performed. Fireﬂy luciferase activities
were normalized to coexpressed renilla luciferase activities. (D) HepG2
cells were used for transfection. The experiment was performed as
described in (C). Mean values ( SD) of representative experiments
performed in triplicate are shown.
A
180:         … TGGGCGGGAC …
180mut:   … TGTTCGGGAC …
Sp1/3
0
50
100
150
200
250
300
350
400
180 180mut 150 120
R
e
l
a
t
i
v
e
 
l
u
c
i
f
e
r
a
s
e
 
a
c
t
i
v
i
t
y
B
0
50
100
150
200
250
300
350
400
SV40 SV40-E1 SV40-E2
R
e
l
a
t
i
v
e
 
l
u
c
i
f
e
r
a
s
e
 
a
c
t
i
v
i
t
y
Vector
Figure 5. A GC-box mediates transcriptional activity of the 180bp core
promoter. (A) A3.01T cells were transfected with reporter plasmid
pGL3-Basic containing 180, 150 or 120bp of the A3G promoter. The
two G-to-T substitutions introduced into the GC-box of the 180bp
fragment (180mut) are speciﬁed. After 48h, cells were harvested for
luciferase assay. Fireﬂy luciferase activities were normalized to
coexpressed renilla luciferase activities. Mean values ( SD) of a
representative experiment performed in triplicate are shown.
(B) pGL3-Promoter reporter plasmids containing the regions E1 or
E2 (see Figure 1) upstream of the SV40 promoter were transfected into
A3.01T cells. Fireﬂy luciferase activities after 48h were normalized to
coexpressed renilla luciferase activities. Mean values ( SD) of a
representative experiment performed in triplicate are shown.
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promoter serves as a binding site for Sp1 and Sp3.
To show binding of Sp1 and Sp3 factors also in the
context of the endogenous A3G promoter, a chromatin
immunoprecipitation (ChIP) assay was performed.
Sp1 and Sp3 antibodies, but not an actin antibody,
immunoprecipitated the A3G promoter in A3.01T cells
(Figure 6C, upper panel). In contrast, no PCR signal was
received with a primer pair recognizing a region in the
A3G gene  4000bp downstream of the Sp1/Sp3–binding
site (Figure 6C, lower panel). Only the positive controls
showed a DNA band, with an A3G expression plasmid or
the sheared and cross-linked input DNA used as template.
This demonstrates the binding of Sp1 and Sp3 transcrip-
tion factors to the endogenous A3G promoter.
Silencing ofSp1and Sp3reduces A3G promoter activity
To conﬁrm the role of Sp1 and Sp3 in regulation of A3G
promoter activity, we silenced their translation via RNA
interference. Functionality of the siRNAs directed against
Sp1 or Sp3 was conﬁrmed by western blot analysis:
protein levels of Sp1 as well as the long and short
isoforms of Sp3 were strongly reduced in the presence of
150 or 300ng speciﬁc siRNA (Figure 7A). An unspeciﬁc
control siRNA had no inﬂuence (Figure 7A). We then
cotransfected the luciferase reporter plasmid containing
the 180bp A3G promoter together with 100ng siRNA
using an optimized protocol for the cotransfection of
plasmid plus siRNA. This resulted in a 31–43% reduction
of luciferase activity in the presence of Sp1- or Sp3-speciﬁc
siRNA compared to the control siRNA. In contrast, no
inﬂuence on transcriptional activity of the 150bp frag-
ment, which does not contain the Sp1/Sp3-binding motif,
was observed. Thus, both Sp1 and Sp3 factors are
mediating transcriptional activity of the A3G promoter.
DISCUSSION
Shortly after the discovery of APOBEC3G, it became
clear that this human gene plays an important role in
antiretroviral defense (4). Originally identiﬁed as a
restriction factor of HIV-1 infection, expression of
APOBEC3G was found in human peripheral blood
lymphocytes and macrophages, which represent the main
target cells for HIV-1 (32). In addition, the protein was
detected in lung, liver, spleen, testis and ovary, but little is
known about its transcriptional regulation (29,32,47). To
address this question, we cloned the human APOBEC3G
promoter and analyzed its regulation in T cells. Applying
50-RACE, we identiﬁed multiple start sites for transcrip-
tion of the A3G gene. This observation is consistent with
the fact that the gene appears to lack canonical CCAAT
and TATA boxes (32), a condition often associated with
multiple transcriptional start sites (49–51). However, one
single start site was detected in 6 of 19 clones and was
designated as þ1. This TSS is located 66bp upstream of
the start of the published mRNA sequence (GenBank
TM
NM021822).
We cloned a 1025bp promoter, which ranges from
position  959/þ66 relative to the identiﬁed TSS.
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Figure 6. Sp1 and Sp3 bind to the GC-box present in the A3G
promoter. (A) Nuclear extracts of A3.01T cells were incubated with
a
32P-labeled commercial Sp1 oligonucleotide probe (Sp1cons) or
labeled probes homologous to the unmodiﬁed or mutated E2 region
(see Figure 1) of the A3G promoter (APO-Sp1/3 and APO-Sp1/3mut).
Protein–DNA complexes were separated by polyacrylamide electro-
phoresis and detected by autoradiography. EMSA was performed with
a 1- or 30-fold molar excess of unlabeled APO-Sp1/3 probe
(competitor, lanes 6 and 7) or APO-Sp1/3mut probe (competitor
mut., lanes 12 and 13). (B) Sp1- and Sp3-speciﬁc antibodies were added
to the EMSA reactions resulting in a supershift (ss) of the respective
antibody–protein–oligo complexes (lanes 3, 4, 7, 8, 11, 12).
(C) ChIP assay was performed with DNA from A3.01T cells.
Immunoprecipitation was performed with antibodies against Sp1, Sp3
or actin. PCR primer pairs speciﬁc for the A3G promoter (upper panel)
or the A3G gene (lower panel) were used. As positive controls, the
sheared and cross-linked DNA before the immunoprecipitation step
(input) or a plasmid carrying the target sequence (plasmid) was used
as template.
3792 Nucleic Acids Research, 2007, Vol. 35, No. 11Luciferase reporter assays showed that this promoter was
transcriptionally active in A3.01T cells. Treatment with
the phorbol ester TPA did not further enhance transcrip-
tional activity, although upregulation of A3G mRNA
levels in T cells by TPA has been described (33). Rose
et al. used actinomycin D to block further transcription
and did not ﬁnd evidence for enhanced mRNA stability.
Therefore, the authors suggested that an enhanced
transcription rate could be responsible for the increased
amount of A3G mRNA after TPA treatment. However,
the promoter analysis we performed indicates a diﬀerent
mechanism that is independent of transcriptional regula-
tion. In addition, we observed that the A3G promoter was
not inducible by IFN-a or IFN-g in A3.01T cells, whereas
in the hepatic cell line HepG2, a moderate induction was
measured. It has been described previously that A3G gene
expression is upregulated by interferons in hepatocytes
and macrophages (46–48,52). In this context, two inter-
feron-responsive elements have been identiﬁed at the
positions  6/þ9 and þ1/þ15 relative to the TSS (48).
Consistent with this data, we observed an interferon
induction in hepatocytes for the fragments ranging
between 1025 and 120bp length. The activity of the
60bp fragment that does not contain these motifs was not
aﬀected. Thus, the induction we observed was most likely
mediated by the described interferon-responsive elements.
However, according to our results, these motifs can
enhance transcription in hepatic cells, but not in T cells.
This is surprising, since IFN-a-inducible signaling
cascades are present in A3.01T cells: we showed that the
control plasmid harboring interferon-responsive GAS
elements was markedly induced by IFN-a treatment. In
contrast, the GAS element was not responsive to IFN-g
treatment in these cells, suggesting that our T cell line was
not able to mediate IFN-g-induced signals. So far,
enhanced A3G promoter activity by interferons is clearly
described in hepatocytes and macrophages, whereas the
situation in T cells is still unclear. A recent study found no
inﬂuence of IFN-a or IFN-g on A3G expression in resting
primary blood lymphocytes (52). Another publication
describes an enhanced expression of A3G after IFN-a
treatment in resting primary CD4T cells, but not in
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Figure 7. Silencing of Sp1 and Sp3 reduces A3G promoter activity. (A) HeLa cells were transfected with 150 and 300ng of unspeciﬁc, Sp1-speciﬁc or
Sp3-speciﬁc siRNA. After 48h, cells were harvested and Sp1 and Sp3 proteins were detected by western blot analysis. As loading control, protein
levels of tubulin are shown. (B) HeLa cells were cotransfected with reporter plasmid pGL3-Basic containing 180 or 150bp of the A3G promoter and
siRNA. Hundred nanogram of unspeciﬁc siRNA (control), Sp1-speciﬁc siRNA (Sp1), Sp3-speciﬁc siRNA (Sp3) or a mixture of 50ng Sp1-speciﬁc
plus 50ng Sp3-speciﬁc siRNA (Sp1þSp3) were used. Fireﬂy luciferase activities after 48h were normalized to coexpressed renilla luciferase activities.
Mean values ( SD) of a representative experiment performed in triplicate are shown.
Nucleic Acids Research, 2007, Vol. 35, No. 11 3793activated T cells (53). This observation is not contra-
dictory to our results since T cell lines are mitotically
active and therefore rather in an activated than in a resting
state. In conclusion, the current data suggests that
regulation of the A3G promoter activity by interferons
is dependent on the cell type and possibly also from the
cellular activation status.
We additionally analyzed the inﬂuence of HIV-1
proteins on A3G promoter activity. The HIV-1 Vif
protein is neutralizing the antiviral function of A3G by
a multitude of ways. Targeting the A3G protein for
proteasomal degradation is considered to be the main
mode of action (37–41), but it becomes more and more
clear that other mechanisms are also involved. There is
evidence that Vif also promotes exclusion of A3G from
the virus particles and an inﬂuence on the A3G translation
process is discussed (8,42,43). The question whether Vif
alters transcription controlled by the A3G promoter has
not been analyzed so far. Our analysis indicates that
transcription from the A3G promoter is unaﬀected by Vif
or other HIV-1 proteins. Taken together, in T cell lines,
the A3G promoter appears constitutively active.
By generating a series of 50 deletions, we showed that
the core promoter is located within the region  114/þ66
relative to the TSS. This 180bp promoter was transcrip-
tionally active in the lymphoid, myeloid and hepatic cell
lines we tested, indicating that ubiquitous transcription
factors are involved in regulation of A3G gene transcrip-
tion. A GC-box with the sequence TGGGCGGGAC was
identiﬁed at position  87/ 78 of the A3G promoter. This
GC-box is essential for basal promoter activity, since
changing the motif to TGTTCGGGAC by introducing
two point mutations strongly reduced A3G promoter
activity. The transcriptional potency of the GC-box was
further demonstrated by cloning it upstream of an SV40
promoter. This resulted in a 4-fold enhanced transcription
rate. The hypothesis that a general transcription factor is
involved in regulation of A3G transcription was con-
ﬁrmed by EMSA. Supershift analysis showed that the
transcription factors Sp1 and Sp3 which are ubiquitously
expressed in mammalian cells, bind speciﬁcally to the
identiﬁed motif. In addition, the binding of Sp1 and Sp3
to the endogenous A3G promoter was demonstrated by a
chromatin immunoprecipitation assay. This observation is
consistent with the results of the 50-RACE, since Sp1 is
known to play an important role for RNA polymerase II
to bind to the transcription initiation site in TATA-
boxless promoters and is associated with multiple
transcription initiation sites (54–56). We also tested
whether overexpression of Sp1 or Sp3 proteins had an
inﬂuence on A3G promoter activity. Luciferase assays
revealed that A3G promoter activities remained
unchanged (data not shown), most probably due to the
high basal expression level of the endogenous Sp1 and/or
Sp3 proteins. The Sp family of transcription factors is
involved in transcriptional regulation of many house-
keeping, tissue-speciﬁc, viral and inducible genes (57).
Whereas Sp1 typically acts as an activator, Sp3 can serve
as a repressor or activator (57). However, in the context of
the A3G promoter, both transcription factors serve as
activators, as shown by siRNA-mediated silencing of the
single factors. Although siRNAs directed against Sp1 or
Sp3 signiﬁcantly reduced transcription controlled by the
180bp promoter, transcriptional activity was not reduced
to the level of the 150bp fragment. This can be explained
by the remaining low amounts of Sp1/Sp3 proteins which
can be seen in the western blot analysis. Alternatively,
other transcription factors could be involved in A3G
regulation.
Our results also provide information about the regula-
tion of APOBEC3F (A3F), another member of the human
APOBEC3 family. A3F is expressed in many human
tissues that also express A3G and both proteins have been
shown to form heteromultimers, which are most likely
generated through binding to an RNA intermediate
(26,29,30). A3F only diﬀers in 16nt from the 560nt
upstream of the TSS of A3G (GenBank
TM DQ146365 and
DQ147772). The 180-bp core promoter region, which we
identiﬁed for A3G has 100% identity with the A3F
sequence. Therefore, Sp1/Sp3 transcription factors are
most likely also mediating basal transcription of the A3F
gene.
Our study revealed that the human A3G gene is
controlled by a promoter with multiple transcriptional
start sites. In A3.01T cells, the A3G promoter appears
constitutively active and is not inducible by TPA, type I or
II interferons or by HIV-1 proteins. The core promoter is
located within a region of 180bp at position  114/þ66
relative to the TSS. A GC-box is crucial to the function of
the core promoter and represents a binding site for Sp1
and Sp3 transcription factors. Our results can serve as a
basis for future studies aimed at understanding how A3G
and A3F expression is controlled in diﬀerent tissues and
how these restriction factors can be used to develop novel
therapeutic strategies against HIV-1 infection.
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